Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Universal Ibogaine Inc ( (TSE:IBO) ) has provided an announcement.
Universal Ibogaine Inc. has provided an update on its delayed year-end 2025 financial filings, confirming it remains under a management cease trade order and will miss the January 30, 2026 deadline to file its audited financial statements, MD&A and officer certifications. The company says completion of the audit is tied to its ongoing restructuring and potential asset sale, and it will continue issuing bi-weekly default status reports while maintaining that no new material changes have occurred beyond those disclosed.
As part of its restructuring, Universal Ibogaine has temporarily closed its Kelburn Recovery Centre near Winnipeg and is negotiating a potential sale of all or part of that property, with proceeds intended to fund completion of the audit and repay outstanding convertible debt that matured in late 2025. The company plans to pivot more fully toward its core medical research business after any sale, including advancing a Clinical Trial Application to Health Canada for ibogaine-based treatment of addiction, a shift that could reshape its operational footprint and financial position while refocusing on its drug development ambitions.
More about Universal Ibogaine Inc
Universal Ibogaine Inc. is a Canadian life sciences company focused on transforming addiction treatment by developing medicalized ibogaine-based therapies. The company’s primary effort is a planned Canadian clinical trial targeting opioid use disorder, with an eventual strategy to commercialize its treatment protocol globally via licensing agreements.
Average Trading Volume: 528,623
Technical Sentiment Signal: Sell
Current Market Cap: C$2.75M
Learn more about IBO stock on TipRanks’ Stock Analysis page.